Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07503444 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
A Phase 3 study, sponsored by UCB Biosciences.
- Not yet
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT07503444 is a Phase 3 study that has not yet begun recruiting, run by UCB Biosciences. The registered enrollment target is 200 participants.
The verdict
NCT07503444, a Phase 3 study, has not yet begun recruiting, sponsored by UCB Biosciences.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
Interventions
- OTHER Placebo
- DRUG fenfluramine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2030-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07503444
The ClinicalTrials.gov registry entry for NCT07503444 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07503444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07503444 about?
NCT07503444 is a clinical study titled "A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome". The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
What is the current status of trial NCT07503444?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2026-06-30. Estimated completion is 2030-11-15.
What interventions are being tested in trial NCT07503444?
The interventions under investigation include: Placebo (OTHER), fenfluramine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT07503444?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.